Gyre Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ping Zhang
- Full Time Employees
- 579
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 12770 High Bluff Drive San Diego CA United States of America 92130
- IPO Date
- Apr 12, 2006
- CIK
- 0001124105
- Website
- gyretx.com
- Similar Companies
- Business
- Gyre Therapeutics, Inc. (Nasdaq: GYRE) is a biopharmaceutical company focused on the development and commercialization of small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ fibrosis diseases, including idiopathic pulmonary fibrosis, liver fibrosis, pneumoconiosis, and metabolic dysfunction-associated steatohepatitis (MASH). Founded in 2002 and headquartered in San Diego, California, the company offers commercial-stage products ETUARY (pirfenidone), approved in China for idiopathic pulmonary fibrosis and under Phase 3 trials for pneumoconiosis, dermatomyositis-associated interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and radiation-induced lung injury; avatrombopag, launched in China in March 2025 for thrombocytopenia in chronic liver disease and immune thrombocytopenic purpura; and nintedanib, planned for launch in China in 2025 for pulmonary fibrosis indications; while advancing a pipeline that includes hydronidone (F351), a pirfenidone analogue in Phase 3 for chronic hepatitis B-associated liver fibrosis in China with NDA filing expected in late 2025 and under U.S. IND for MASH fibrosis; F573 in Phase 2 for acute-on-chronic liver failure; F528 in preclinical development for chronic obstructive pulmonary disease; and F230 for pulmonary arterial hypertension. Through its 65.2% indirect majority interest in Gyre Pharmaceuticals (Beijing Continent Pharmaceuticals Co., Ltd.) acquired in October 2023, Gyre conducts operations primarily in China and pursues U.S. development, targeting patients with chronic liver and lung diseases via partnerships with hepatologists, hematologists, pulmonologists, and oncologists. Recent developments include the March 2025 NMPA approval for a pirfenidone trial in radiation-induced lung injury entering oncology supportive care, completion of enrollment in the Phase 3 pneumoconiosis trial in October 2025, positive topline Phase 3 results for hydronidone in chronic hepatitis B liver fibrosis announced for presentation at AASLD 2025, and Q1 2025 revenue of $22.1 million driven by expanding commercialization efforts.
Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm
New Strong Sell Stocks for May 27th
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company
Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Head-To-Head Contrast: Gyre Therapeutics (NASDAQ:GYRE) versus Tenax Therapeutics (NASDAQ:TENX)
Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline
Analyzing Gyre Therapeutics (NASDAQ:GYRE) and ImmunityBio (NASDAQ:IBRX)
Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting
Gyre Therapeutics, Inc. (GYRE) Q3 Earnings Surpass Estimates
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
New Strong Sell Stocks for Oct. 17th
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors